Emgality

Selected form

There is no image.

Galcanezumab

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Emgality

Property	Description
Active ingredient	Galcanezumab (INN)
Form	Solution for injection (prefilled syringe/pen)
Pharmacological class	Monoclonal antibody (CGRP antagonist)
Origin	Biologic medicine (humanized IgG4)
Administration	Subcutaneous

What Type of Medicine is Emgality (Galcanezumab)?

Emgality is a biologic medicine delivered as a solution for injection that contains the active substance Galcanezumab. It is classified as a highly specific monoclonal antibody and functions as a Calcitonin Gene-Related Peptide (CGRP) antagonist. This classification means it is a complex, lab-engineered protein manufactured to precisely target one specific physiological pathway, distinguishing it from traditional chemically synthesized drugs.

The core of Emgality is Galcanezumab, a humanized Immunoglobulin G4 (IgG4) monoclonal antibody. This structure allows it to perform selective binding to the CGRP ligand, a key protein involved in nervous system signaling. This highly targeted mechanism is characterized by its ability to reduce pathway activity.

Emgality's Composition and Physical Form

The medicine is supplied as a sterile aqueous solution for injection, specifically intended for subcutaneous administration via a single-dose prefilled pen or syringe. This method of delivery is necessary because, as a large protein, Galcanezumab would be inactivated if taken orally. The solution itself consists of the active ingredient dissolved in a base containing excipients like sucrose and polysorbate 80, ensuring stability and correct concentration for its intended use.

What is the General Purpose of CGRP Antagonists?

The general purpose of Emgality is to interrupt a key pain and signaling pathway in the body, which is achieved by neutralizing the CGRP ligand. The action of the active substance provides a preventive treatment strategy. Therefore, this CGRP antagonist neutralizes this chemical messenger to reduce the overall frequency and intensity of associated neurovascular mechanisms, offering a management approach for adults.

Regulatory References

What side effects are possible with Emgality?

Possible Side Effects and Safety Information

The official safety profile for Emgality (galcanezumab) is structured by regulatory authorities based on classifications of adverse events reported in clinical trials and post-marketing surveillance.

Frequency-Classified Adverse Reactions

The most commonly reported effects involve the administration site. Adverse reactions are grouped by frequency and body system according to regulatory standards:

Classification	System-Organ Class	Example Adverse Reaction
Very Common (ge 10% )	General Disorders	Injection site pain and reactions
Common (ge 1% to < 10% )	Ear/Labyrinth, Gastrointestinal	Vertigo, Constipation, Pruritus
Uncommon (ge 0.1% to < 1% )	Skin	Urticaria, Rash

Serious Adverse Reactions and Safety Constraints

The potential for Serious Hypersensitivity Reactions is formally documented, including cases of Anaphylaxis and Angioedema, which have been reported and can have a delayed onset, occurring days to weeks after administration. Therefore, Emgality is contraindicated in individuals with a known serious hypersensitivity to the active substance or any of its excipients.

Post-marketing reports also include the occurrence of new-onset or worsening Hypertension and Raynaud’s phenomenon.

Population-Specific Safety Notes

The regulatory label includes specific notes on populations where safety data are limited. For instance, patients with certain major cardiovascular diseases were excluded from clinical trials, meaning safety data are unavailable for this group. The medicine is not approved for the use in pediatric patients (under 18 years of age).

Overdose and Emergency Response

In the event of a suspected overdose of Emgality (galcanezumab), immediate medical attention should be sought. Official regulatory documents mandate that the individual contact emergency services or a poison center for prompt management advice regarding the over-exposure.

The official prescribing information for galcanezumab indicates a limited profile for acute overdose manifestations. Clinical studies involving subcutaneous administration of the medicine at doses up to 600 mg—several times the typical maintenance dose—did not demonstrate dose-limiting toxicity or unexpected acute clinical outcomes. There are no specific regulator-listed severe or life-threatening symptoms documented as a direct toxic consequence of an acute overdose.

Management of an overdose is structured around monitoring and supportive care. Since no specific antidote is known or available to reverse the effects of galcanezumab, the primary regulatory directive is to ensure that the patient is monitored continuously for any signs or symptoms of adverse reactions. Furthermore, appropriate symptomatic treatment must be immediately instituted to manage any clinical changes that may occur. No population-specific differences in overdose management are explicitly stated in the official labels.

Therapeutic Uses of Emgality

Emgality is a medication approved for use in adults for specific neurological conditions.

Quick Facts on Approved Uses

May help with the preventive treatment of migraine in adults.
May help with the treatment of episodic cluster headache in adults.

Emgality (galcanezumab-gnlm) is a prescription treatment that is used for two distinct therapeutic areas in adults. It is available to help in the preventive treatment of migraine, which includes both episodic and chronic forms. The drug is administered to reduce the frequency of headache days. Additionally, Emgality may be used for the treatment of episodic cluster headache in adults. This application may help to reduce the frequency of cluster attacks during the episodic period. Emgality is generally well-tolerated when used as directed by a healthcare provider.

Eligibility and Restrictions for Use

Who Can and Cannot Use Emgality — Official Regulatory Information

Eligibility Scope

Population	Regulatory Status
Allowed	Adults (age ge 18 years).
Contraindicated	Patients with known serious hypersensitivity to galcanezumab or its excipients.
Pediatric (mathbf< 18)	Safety and effectiveness not established; use is not recommended.
Pregnancy	Preferable to avoid (precautionary measure due to limited human data).
Lactation	Unknown if excreted in human milk; use could be considered only if clinically needed.

Condition-Specific Eligibility Rules

Organ Function: No dose adjustment is required for patients with mild or moderate renal or hepatic impairment. However, safety and efficacy are not established in cases of severe renal impairment.
Comorbidity: Patients with recent acute cardiovascular events were excluded from clinical trials, meaning safety data is not available for this population.
Geriatric Use (mathbfge 65): No dose adjustment is required based on drug absorption/clearance, though trials did not include sufficient numbers of older adults to fully assess potential differences in response.

Connection to the overall eligibility profile: Official regulatory documents define Emgality as strictly for the adult population. The only absolute restriction is for individuals with a history of serious allergic reaction to the medicine. For other groups, such as children, pregnant women, and patients with recent major cardiovascular issues, eligibility is constrained by a lack of sufficient clinical data establishing safety or efficacy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents indicate that galcanezumab (the active substance in Emgality) is not expected to cause known pharmacokinetic drug interactions with other medicines.

Galcanezumab is a humanized monoclonal antibody. Unlike many commonly used medicines, it is not metabolized (broken down) by the Cytochrome P450 (CYP450) enzyme system in the liver. As a result, interactions with medicinal products that are substrates, inhibitors, or inducers of CYP450 enzymes are considered unlikely to occur.

Documented Interaction Profile

Interaction Context	Regulatory Statement
Drug Interaction Studies	No formal drug interaction studies have been conducted.
Specific Interacting Medicines	None are explicitly listed in official labeling for effects on galcanezumab exposure or safety.
Required Restrictions	No dose adjustments or co-administration restrictions are mandated due to pharmacokinetic interaction risk.

Summary of Interaction Constraints

The regulatory profile for galcanezumab is structured by the expected absence of clinically significant drug-drug interactions. Because the drug is not metabolized via the CYP450 system, official documentation mandates no special precautions or monitoring requirements related to its use with other medicines based on interaction risk. Patients should continue to inform their healthcare provider about all current medicines, including prescription and non-prescription drugs, vitamins, and herbal supplements.

Mechanism of Action

The core mechanism of Galcanezumab involves the selective binding and neutralization of the circulating Calcitonin Gene-Related Peptide (CGRP) ligand. As a humanized monoclonal antibody, the drug physically sequesters the CGRP molecule, thereby preventing this neuropeptide from binding to and activating its corresponding receptor ( CGRP-R) on target cells. By blocking the CGRP ligand, the drug directly modulates the cascade of events within the trigeminovascular system—the sensory nerve network crucial for nociceptive signaling. This action influences the downstream signaling of CGRP, including effects on neurogenic inflammation and vascular changes in the meninges. The resulting physiological effect is a reduction of peripheral and central sensitization within these pathways. The sustained neutralization of CGRP diminishes the overall activity and excitability of the nociceptive pathways, influencing the magnitude of sensory signal transmission and modulating the functional dynamics of the trigeminal system.

Dosage and Administration Information

Emgality (galcanezumab-gnlm) is administered via subcutaneous injection using a single-dose prefilled pen or syringe. Patients and caregivers must receive proper training from a healthcare professional on the preparation and administration of the medication before use. The dosage schedule varies based on the condition being treated, so always follow your prescriber's instructions.

Administration Details

Preparation Step	Instruction
Temperature	Allow the pen or syringe to sit at room temperature for 30 minutes before injection; do not warm it with heat sources.
Inspection	Inspect the solution visually. It should be clear to opalescent, and colorless to slightly yellow or brown. Do not use if it is cloudy, contains visible particles, or is frozen.
Injection Sites	The recommended injection sites are the abdomen (excluding the two inches around the navel) or the thigh. A caregiver may administer the injection in the back of the upper arm or buttocks. Avoid areas where the skin is tender, bruised, red, or hard. Always rotate the injection site.

General Guidelines

Emgality is for single-use only and must not be shared or reused. Do not put the base cap back on the prefilled pen after removal, as this could damage the needle. After the injection is complete, immediately dispose of the used pen or syringe in an approved sharps disposal container.

If a dose is missed, administer it as soon as possible, and then resume the regular monthly dosing schedule from that date.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Emgality

Evidence for use in Preventing Migraine Headaches

Research explored the clinical evaluation of Emgality using large, multi-national, double-blind Randomized Controlled Trials (RCTs), which were used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations. Study populations included adults diagnosed with either episodic migraine or chronic migraine.

The main outcomes related to physical discomfort that research examined were the overall mean change in the number of monthly migraine headache days (MHDs). Studies also monitored the proportion of participants who experienced specific percentage reductions (50%) in MHDs. The primary data for the studies was collected over initial double-blind treatment phases lasting either three or six months. Long-term effects are not fully established beyond the observation periods of the original trials.

Evidence for use in Treating Episodic Cluster Headache

Research was evaluated in a single Phase 3, double-blind, placebo-controlled trial. This study was relevant in trials assessing short-term or episodic symptom patterns and was conducted during periods of increased symptom activity. The main study outcome monitored in this research scenario was the overall mean change in weekly cluster headache attack frequency.

The trial results apply only to the populations studied and were based on a very short duration of primary outcome measurement (three weeks). The sample size was modest because the study was terminated early due to recruitment challenges. Comparative evidence with established therapies is limited. Furthermore, research did not examine chronic cluster headache.

Evidence in Special Populations and Research Gaps

Study observations for both conditions are based on short-term to intermediate follow-up durations (ranging from three weeks to six months). Open-label extension (OLE) studies provided researchers with data observed in patients for extended time intervals, sometimes for up to 12 months of continuous treatment.

The initial evidence was observed in a generally healthy adult population between 18 and 65 years of age. Data for certain groups remain insufficient, as the primary trials generally excluded patients older than 65 years. Similarly, individuals with certain significant cardiovascular conditions were also excluded, meaning data for certain groups remain insufficient. Subgroup findings are uncertain for these excluded populations.

Frequently Asked Questions (FAQ)

Common questions about Emgality (FAQ)

Q: What is Emgality used for?

Emgality (galcanezumab) is a prescription medicine used to prevent migraine headaches in adults. It is also used to treat episodic or chronic cluster headache in adults.

Q: How does Emgality work?

Emgality is a type of medicine called a calcitonin gene-related peptide (CGRP) antagonist. CGRP is a naturally occurring protein that plays a role in causing migraine and cluster headaches. Emgality works by blocking CGRP from attaching to its receptors, which helps to prevent migraine attacks and reduce the frequency of cluster headaches.

Q: How is Emgality administered?

Emgality is given as an injection under the skin (subcutaneous injection). It is available as a prefilled syringe or a prefilled pen. After training, patients may be able to administer the injections themselves at home.

Q: What are the common side effects of Emgality?

The most common side effects are reactions at the injection site (such as pain, redness, or itching), as well as constipation and itching (pruritus) affecting the whole body.

Q: Can I use Emgality if I am pregnant?

It is not known if Emgality will harm an unborn baby. You should tell your healthcare provider if you are pregnant or plan to become pregnant before starting this medication.

How should Emgality be stored and disposed of?

Official Storage and Disposal Instructions

Emgality (galcanezumab) is a biologic medicine with mandatory, label-defined storage requirements to maintain its integrity.

Storage Rule	Requirement
Primary Temperature	Store in a refrigerator between mathbf2^circC and mathbf8^circC (mathbf36^circF to mathbf46^circF).
Physical Protection	Do not freeze or shake the product. Keep it in the original carton to protect it from light.
Room Temp Stability	May be kept at temperatures up to mathbf30^circC (mathbf86^circF) for a single period of up to 7 days, after which it must be discarded and cannot be returned to the refrigerator.
Child Safety	Keep out of the sight and reach of children.

Used Emgality prefilled pens or syringes must be immediately placed in a puncture-resistant sharps disposal container after use. Regulatory guidelines prohibit disposing of the used product or unused medicine in household trash or via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

USA

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z